CDH1 and non-small cell lung carcinoma: The first report of a trend toward EMT in EGFR-mutant NSCLC with acquired resistance to EGFR TKI gefitinib came in 2010, when biospecimens from 9 cases of EGFR-mutant lung adenocarcinoma pre- and post-acquisition of resistance to gefitinib were analyzed for expression of epithelial (E-cadherin, γ-catenin) and mesenchymal (vimentin, fibronectin) markers (Uramoto et al., 2010).